This SPA proposes to amend the language provisions for coverage of selective non-legend outpatient drugs. This SPA also updates additional Pharmacy coverage items on the State Plan pages.

This SPA proposes to allow the state to enter into value-based contracts with manufacturers.

This SPA proposes to change the state’s multi-state Supplemental Rebate Agreement arrangement from being with National Medicaid Pooling Initiative (NMPI) to joining the Sovereign States Drug Consortium (SSDC). The SPA also proposes to allow the state to enter into individual Supplemental Rebate Agreements directly with manufacturers.

This SPA proposes to modify language on the Pharmacy coverage pages to reflect coverage of selective non-prescription (over-the-counter) medications, as well as removing language regarding coverage of cosmetic and hair growth agents from the excluded drug list.

CMS is approving this time-limited state plan amendment to allow the state to implement temporary policies while returning to normal operations after the COVID-19 national emergency. The purpose of this amendment is to extends ARPA Initiative regarding PDN_C19 Test and Specimen Collection.

This SPA proposed to revise the state’s reimbursement rate for physician administered drugs such that it will continually align with the Medicare Fee Schedule reimbursement rate.

This SPA proposes to modify language on the Pharmacy coverage pages to reflect coverage of selective over-the-counter (OTC) medications.

This amendment proposes to allow the state to add coverage for selected drugs that treat obesity

This amendment proposes to establish two eligible pediatric residential health care facilities to improve the quality of care for young adults with medical fragility.